Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.

Pfizer is paying over $7 billion to buy clinical-stage biotech Metsera. This gives it a wedge into the hottest segment of the pharma industry. Yet, shares of the giant drugmaker remain at depressed ...

LONDON (Reuters) -AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients ...

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop ...

The researchers found that, compared to the AGHE, the Mediterranean diet resulted in a significant decrease in waist ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the ...

The clinical trial that Eli Lilly terminated was expected to enroll 180 people and finish in late 2026. The trial had been measuring how well Bimagrumab stimulates weight loss and preserves muscle ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Pharmacy benefit managers are working on a proposal to voluntarily change some business practices in an effort to avoid new ...